Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Company has three brands (Lantus, Allegra, Combiflam) in top 100 pharmaceutical brands in India (IQVIA TSA MAT December 2020). MAT growth was 8% in CY20 (vs 4% for IPM)
- Sanofi reported Total revenue for Q4 FY23 of ₹736 Crore, up from ₹707 Crore year on year depicting a growth of 4%.
- Total Expenses for Q4 FY23 of ₹507 Crore down, from ₹512 Crore year on year, a decline of 1%.
- Consolidated Net Profit of ₹190 Crore, down 20% from ₹238 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹82.67, down 20% from ₹103.51 in the same quarter of the previous year.